Propanc Biopharma

Propanc Biopharma Quick Ratio

The Quick Ratio (Acid Test) of Propanc Biopharma (PPCB) as of Oct 24, 2026 is 2.54. In the previous year, Quick Ratio (Acid Test) was 1.50 — a change of 69.91% (higher).

Quick Ratio

2.54

YoY

69.91%

Last updated:

Quick Ratio (Acid Test) of Propanc Biopharma is 2026 2.54 . Quick Ratio (Acid Test) of Propanc Biopharma was 2025 1.50 . It decreases by 69.91% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Propanc Biopharma Stock analysis

What does Propanc Biopharma do? Propanc Biopharma Inc develops cancer treatments through research and development, focusing on preventing tumor recurrence and metastases. The company's products include PRP, a formulation of trypsinogen, chymotrypsinogen, and amylase, which targets tumor cells specifically without affecting normal cells. PRP-DCM is another product in their portfolio. The firm aims to commercialize long-term therapies for cancer treatment and prevention, targeting patients with solid tumors seeking to avoid tumor recurrence and spread. Propanc Biopharma's business model centers on developing and selling its proprietary pro-enzyme therapies. The company's primary products, PRP and PRP-DCM, are designed to control tumor growth and prevent metastasis. They target healthcare providers and patients requiring long-term cancer management solutions. The company's development-stage status indicates that it is still in the research phase, with no commercial sales yet, but it plans to bring these therapies to market once development is complete. The company's strategy involves creating therapies that specifically target cancer cells, reducing side effects compared to traditional treatments. Their focus on solid tumors and prevention of recurrence aligns with a growing market need for more targeted cancer therapies. Propanc Biopharma's approach to developing pro-enzyme treatments positions them as a specialized player in the oncology sector, aiming to address unmet medical needs in cancer care. Propanc Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Propanc Biopharma stock

Quick Ratio (Acid Test) of Propanc Biopharma is 2.54 in 2026.

Quick Ratio (Acid Test) of Propanc Biopharma changed from 1.50 to 2.54, representing a 69.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Propanc Biopharma since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Propanc Biopharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Propanc Biopharma

All Key Metrics — Propanc Biopharma